Beam Therapeutics GAAP EPS of $2.33, revenue of $114.1M
Source: SeekingAlpha
2026-02-24 07:27:07 ET
More on Beam Therapeutics
- Beam Therapeutics Inc. (BEAM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Beam Therapeutics: Pivoting From Platform To Execution Stage
- Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal
- Beam Therapeutics shares jump on progress in precision genetic medicines and 2026 strategic plans
- Biggest stock movers Monday: Credit card firms, SNCY, BEAM and more
Read the full article on Seeking Alpha
For further details see:
Beam Therapeutics GAAP EPS of $2.33, revenue of $114.1M
Beam Therapeutics Inc.
NASDAQ: BEAM
BEAM Trading
-0.58% G/L:
$27.20 Last:
395,042 Volume:
$27.40 Open:
BEAM Latest News
February 24, 2026 07:01:00 am
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
February 24, 2026 07:00:00 am
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
BEAM Stock Data
$2,726,631,745
90,820,075
0.13%
130
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
